Clinical trials: sponsored by Fujian Cancer Hospital
Pulmonary Adenosquamous Carcinoma
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
This is a prospective, multi-center, single-arm clinical trial.
- Trial name
- ARISE (NCT04354961)
- Testing
- Almonertinib
- Where
- 18 sites in China
- Volunteers
- 13 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer, Radiotherapy
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.
- Conditions
- Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
- Trial name
- NCT06101966
- Testing
- external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus immunotherapy with concurrent chemoradiotherapy (CCRT) or RT alone in patients with stage III-IVa nasopharyngeal carcinoma(NPC), in order…
- Trial name
- NCT06095167
- Testing
- without concurrent cisplatin chemotherapy, with concurrent cisplatin chemotherapy
- Where
- China
- Volunteers
- 476 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Neoplasms, Esophageal Diseases
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal…
- Conditions
- Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
- Trial name
- NCT05624099
- Testing
- camrelizumab, Paclitaxel drugs, Platinum drug
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fujian Cancer Hospital
Advanced Solid Tumor
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors.
- Trial name
- NCT06078670
- Testing
- CVL218
- Volunteers
- 96 people
- Sponsor
- Fujian Cancer Hospital
Cervix Carcinoma
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
This study aims to develop a diagnostic nomogram based on clinical factors with the prediction values of vaginal invasion in cervical cancer to optimize the treatment plan and surgical procedures.
- Trial name
- NCT06039982
- Testing
- no intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer
A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).
A Single-Center Retrospective Study About Efficacy and Safety of Eribulin-Based Regimen in the Treatment of Metastatic Triple-Negative Breast Cancer and Comparison With Other Chemotherapy Regimen
- Trial name
- ERI-Based-01 (NCT05953909)
- Testing
- Eribulin-Based Regimen, nab-paclitaxel based regimen, Other Chemotherapy Regimen
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Cancer Hospital
Malignant Melanomas
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
The goal of this clinical trial is provide new treatment for patients with advanced melanoma who have failed previous immunotherapy.
- Trial name
- NCT05928962
- Testing
- Recombinant Human Adenovirus Type 5 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Squamous Cell Carcinoma
This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in…
- Trial name
- NCT05927844
- Testing
- XH-30002 capsule, Afatiinb tablet
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Gastrointestinal Tumors
Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%.
- Trial name
- NCT05922358
- Testing
- Anti-allergic treatment
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of advanced gastric cancer after first-line resistance
- Trial name
- NCT05751265
- Testing
- Tislelizumab, 5Fu, Paclitaxel injection
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Immunotherapy
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Trial name
- NCT05479240
- Testing
- Tislelizumab, Capecitabine, oxaliplatin
- Volunteers
- 94 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
The purpose of this study is to investigate the efficacy and safety of Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses.
- Trial name
- NCT05897138
- Testing
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Small Cell Lung Cancer
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab
- Trial name
- NCT05882630
- Testing
- Surufatinib,Serplulimab,Etoposide,Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Thyroid Cancer, Tyrosine Kinase Inhibitor
HRQOL in Locally Advanced Thyroid Carcinoma
The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).
- Conditions
- Thyroid Cancer, Tyrosine Kinase Inhibitor, Health Related Quality of Life
- Trial name
- LATCQOL (NCT05824312)
- Testing
- Tyrosine kinase inhibitor drugs.
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer
- Trial name
- NCT05799443
- Testing
- Tislelizumab, Irinotecan Hydrochloride, cetuximab
- Volunteers
- 23 people
- Sponsor
- Fujian Cancer Hospital
Malignant Melanoma, Liver Metastases
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
This study is the first to explore the efficacy and safety of recombinant human adenovirus type 5 injection combined with PD-1 monoclonal antibody and nab-paclitaxel in the treatment of patients with liver metastases of melanoma…
- Trial name
- NCT05664139
- Testing
- Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated…
- Conditions
- Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor, VEGF
- Trial name
- NCT05675033
- Testing
- Serplulimab and Bevacizumab injection
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
EGFR, NSCLC
Almonertinib Plus Metronomic Oral Vinorelbine
To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.
- Conditions
- EGFR, NSCLC, Third-generation TKI
- Trial name
- NCT05663177
- Testing
- Almonertinib and metronomic oral vinorelbine
- Volunteers
- 40 people
- Sponsor
- Fujian Cancer Hospital
Solid Tumor
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TILs) therapy in patients with Advanced malignant solid tumors.
- Trial name
- NCT05649618
- Testing
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide Capsules
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital